WINTON GROUP Ltd decreased its position in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 48.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,273 shares of the medical instruments supplier’s stock after selling 2,137 shares during the period. WINTON GROUP Ltd’s holdings in West Pharmaceutical Services were worth $284,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Financial Gravity Wealth Inc. acquired a new position in West Pharmaceutical Services during the first quarter worth approximately $25,000. Quadrant Capital Group LLC increased its holdings in shares of West Pharmaceutical Services by 208.7% in the first quarter. Quadrant Capital Group LLC now owns 318 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 215 shares during the period. Manchester Capital Management LLC acquired a new position in shares of West Pharmaceutical Services in the first quarter valued at approximately $33,000. Icon Wealth Partners LLC acquired a new position in shares of West Pharmaceutical Services in the first quarter valued at approximately $46,000. Finally, Private Capital Group LLC increased its holdings in shares of West Pharmaceutical Services by 44.1% in the first quarter. Private Capital Group LLC now owns 673 shares of the medical instruments supplier’s stock valued at $74,000 after purchasing an additional 206 shares during the period. 91.62% of the stock is currently owned by institutional investors.
Shares of NYSE:WST traded down $1.72 during trading on Friday, reaching $135.56. The company had a trading volume of 322,850 shares, compared to its average volume of 339,073. The company has a market cap of $10.12 billion, a price-to-earnings ratio of 48.24, a price-to-earnings-growth ratio of 3.91 and a beta of 1.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.02 and a quick ratio of 2.13. The firm’s fifty day moving average price is $125.39. West Pharmaceutical Services Inc. has a fifty-two week low of $91.75 and a fifty-two week high of $139.59.
West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.72 by $0.17. West Pharmaceutical Services had a return on equity of 16.93% and a net margin of 12.94%. The firm had revenue of $469.70 million for the quarter, compared to the consensus estimate of $459.90 million. During the same period in the previous year, the business earned $0.70 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities research analysts expect that West Pharmaceutical Services Inc. will post 3.07 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 6th. Investors of record on Wednesday, October 23rd will be paid a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, October 22nd. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.44%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.35%.
A number of research analysts have recently issued reports on WST shares. Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. William Blair started coverage on West Pharmaceutical Services in a report on Tuesday, April 23rd. They issued an “outperform” rating and a $112.16 target price on the stock. Bank of America raised West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a report on Friday, July 26th. Finally, Jefferies Financial Group lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 target price on the stock. in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $123.05.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Featured Story: Yield Curve
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.